The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Outcomes of patients with Hodgkin lymphoma undergoing alloHSCT after pembrolizumab therapy
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, comments on the results of a study assessing the safety of allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with classical Hodgkin lymphoma (HL) previously treated with pembrolizumab. Overall, whilst the study did not find a significant difference in efficacy when compared with historical controls, it reported a higher rate of acute graft-versus-host disease (GvHD) in patients treated with pembrolizumab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Karyopharma, DSB; Honoraria from Karyopharma, Merck; Research funding from Merck
